Table 1.
Data from 11 randomized controlled trials
| Author | Country | Publication time | Chemotherapy regimens | IPT | Surgery | Follow-up (mo) | Quality score |
| (number of death/total) | |||||||
| Rosen HR | Austria | 1998 | MMC+Carbon | 23/46 | 27/45 | 36 | 4 |
| Sautner T | Austria | 1994 | Cisplatin | 29/33 | 31/34 | 60 | 3 |
| Takahashi T | Japan | 1995 | MMC+Carbon | 35/56 | 46/57 | 36 | 3 |
| Yu W | Korea | 2001 | MMC+5-Fu | 55/125 | 72/123 | 60 | 2 |
| Yonemura Y | Japan | 2001 | MMC+CDDP | 44/92 | 27/47 | 60 | 1 |
| Hamazoe R | Japan | 1993 | MMC | 18/42 | 22/40 | 60 | 1 |
| Chen ZX | China | 1996 | DDP | 8/25 | 13/21 | 18 | 1 |
| Zhang WS | China | 1998 | 5-Fu | 14/37 | 15/26 | 36 | 1 |
| Fujimoto S | Japan | 1998 | MMC | 27/71 | 36/70 | 96 | 1 |
| Tan CQ | China | 2000 | MMC | 2/22 | 11/29 | 36 | 1 |
| Gao ZA | China | 2002 | MMC+DDP+HCPT | 17/60 | 31/60 | 36 | 2 |